Titel: Kinoloner bör inte ges i monoterapi vid infektion med Pseudomonas aeruginosa 2006 nr 14 sid 1121-2

Läs/ladda hem artikeln: Översikt Fullständig referenslista Artikeln i pdf-format (utskriftskvalitet) Sid 1121 Sid 1122 Om Läkartidningens fulltext på Internet Hämta Acrobat Reader

Ämnesord:
Läkemedelsresistens, bakteriell
Pseudomonas aeruginosa
Pseudomonasinfektioner
Kinoloner











Sök liknande artiklar (ny funktion på försök)

Referenser:
1. Lytsy B, Cars O, Torell E. Kinoloner - bot som blivit hot. Läkartidningen 2005;102(48):3651-9.
2. Kohler T, Michea-Hamzehpour M, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41(11):2540-3.
3. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;33 Suppl 3:S147-56.
4. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44(12):3322-7.
5. Roveta S, Schito AM, Marchese A, Schito GC. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Int J Antimicrob Agents 2005;26(5):366-72.
6. Join-Lambert OF, Michea-Hamzehpour M, Kohler T, Chau F, Faurisson F, Dautrey S, et al. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. Antimicrob Agents Chemother 2001;45(2):571-6.
7. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003;52(1):11-7.
8. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005;40 Suppl 2:S99-104.
9. Lomholt JA, Kilian M. Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis. Br J Ophthalmol 2003;87(10):1238-40.
10. Läkemedelsverket. Information från Läkemedelsverket. 2005;16(5):48-49.
11. Juan C, Gutierrez O, Oliver A, Ayestaran JI, Borrell N, Perez JL. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect 2005;11(11):887-92.
12. Fink MP, Snydman DR, Niederman MS, Leeper KV, Jr., Johnson RH, Heard SO, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994;38(3):547-57.
13. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42(3):521-7.
14. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43(6):1379-82.
15. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daures JP, et al. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 2004;57(3):209-16.
16. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005;65(7):949-91.
17. Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother 2005;56(2):353-9.
18. Ulkur E, Oncul O, Karagoz H, Celikoz B, Cavuslu S. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and silver sulfadiazine 1% (Silverdin) for topical antibacterial effect in Pseudomonas aeruginosa-contaminated, full-skin thickness burn wounds in rats. J Burn Care Rehabil 2005;26(5):430-3.